Current Allergy and Asthma Reports

, Volume 8, Issue 6, pp 465–474 | Cite as

Subcutaneous and sublingual immunotherapy in children: Complete update on controversies, dosing, and efficacy



For this review, articles on immunotherapy dosing in pediatric respiratory allergy were identified via PubMed, through congressional abstracts for 2008, in reference lists of recent review articles, and via personal communication with experts. In pediatric subcutaneous immunotherapy (SCIT), doses shown to be effective, mostly in aluminium-adsorbed preparations administered every 6 weeks, contain 20 μg of group 5 major allergen, 12 μg Bet v 1, 15 μg Fel d 1, and 5 to 20 μg Der p 1. Evidence indicates that SCIT prevents new sensitizations and asthma onset 7 years after discontinuation and reduces symptoms 12 years after a 5-year SCIT course, even though skin reactivity returns. Consistent evidence of effect exists for sublingual immunotherapy in pediatric respiratory allergy with daily 15-to 25-μg grass group 5 major allergen and 6 μg Bet v 1. Der p/f doses of 0.8/0.4 μg three times weekly (up to 27/57 μg daily) demonstrate inconsistent findings. Evidence of effect exists for SCIT in pediatric allergic rhinitis and asthma as treatment and preventive management. Evidence of effect exists for sublingual immunotherapy in pediatric allergic rhinoconjunctivitis and seasonal asthma. Similar results are doubtful for perennial asthma.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Akdis M, Akdis CA: Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007, 9:780–791.CrossRefGoogle Scholar
  2. 2.
    Francis JN, James LK, Paraskevopoulos G, et al.: Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008, 121:1120–1125.PubMedCrossRefGoogle Scholar
  3. 3.
    Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT: Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol 2008, 121:1467–1472.PubMedCrossRefGoogle Scholar
  4. 4.
    Larenas-Linnemann D, Cox LS, Immunotherapy and Allergy Diagnostics Committee of the American Academy of Allergy, Asthma and Immunology: European allergen extract units and potency: review of available information. Ann Allergy Asthma Immunol 2008, 100:137–145.PubMedGoogle Scholar
  5. 5.
    van Ree R, Chapman MD, Ferreira F, et al.: The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008, 63:310–326.PubMedCrossRefGoogle Scholar
  6. 6.
    Cox LS, Linnemann DL, Nolte H, et al.: Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006, 117:1021–1035.PubMedCrossRefGoogle Scholar
  7. 7.
    Valovirta E, Jacobsen L, Ljorring C, et al.: Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy 2006, 61:1177–1183.PubMedCrossRefGoogle Scholar
  8. 8.
    Dreborg S, Agrell B, Foucard T, et al.: A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 1986, 41:131–140.PubMedCrossRefGoogle Scholar
  9. 9.
    Peroni DG, Piacentini GL, Martinati LC, et al.: Doubleblind trial of house-dust mite immunotherapy in asthmatic children resident at high altitude. Allergy 1995, 50:925–930.PubMedCrossRefGoogle Scholar
  10. 10.
    Adkinson NF Jr, Eggleston PA, Eney D, et al.: A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997, 336:324–331.PubMedCrossRefGoogle Scholar
  11. 11.
    Hedlin G, Wille S, Browaldh L, et al.: Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy. J Allergy Clin Immunol 1999, 103:609–614.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang H, Lin X, Hao C, et al.: A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006, 61:191–197.PubMedCrossRefGoogle Scholar
  13. 13.
    Pifferi M, Baldini G, Marrazzini G, et al.: Benefits of immunotherapy with a standardized Dermatophagoides pteronyssinus extract in asthmatic children: a three-year prospective study. Allergy 2002, 57:785–790.PubMedCrossRefGoogle Scholar
  14. 14.
    Tsai YG, Chien JW, Chen WL, et al.: Induced apoptosis of Th2 lymphocytes in asthmatic children treated with Dermatophagoides pteronyssinus immunotherapy. Pediatr Allergy Immunol 2005, 16:602–608.PubMedCrossRefGoogle Scholar
  15. 15.
    Johnstone DE, Dutton A: The value of hyposensitization therapy for bronchial asthma in children-a 14-year study. Pediatrics 1968, 42:793–802.PubMedGoogle Scholar
  16. 16.
    Cools M, Van Bever HP, Weyler JJ, Stevens WJ: Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy 2000, 55:69–73.PubMedCrossRefGoogle Scholar
  17. 17.
    Eng PA, Reinhold M, Gnehm HP: Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002, 57:306–312.PubMedCrossRefGoogle Scholar
  18. 18.
    Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP: Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006, 61:198–201.PubMedCrossRefGoogle Scholar
  19. 19.
    Keskin O, Tuncer A, Adalioglu G, et al.: The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis. Pediatr Allergy Immunol 2006, 17:396–407.PubMedCrossRefGoogle Scholar
  20. 20.
    Jacobsen L, Niggemann B, Dreborg S, et al.: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007, 62:943–948.PubMedCrossRefGoogle Scholar
  21. 21.
    Des Roches A, Paradis L, Menardo JL, et al.: Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997, 99:450–453.PubMedCrossRefGoogle Scholar
  22. 22.
    Pajno GB, Morabito L, Barberio G, Parmiani S: Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000, 55:842–849.PubMedCrossRefGoogle Scholar
  23. 23.
    Inal A, Altintas DU, Yilmaz M, et al.: Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol 2007, 17:85–91.PubMedGoogle Scholar
  24. 24.
    Cevit O, Kendirli SG, Yilmaz M, et al.: Specific allergen immunotherapy: effect on immunologic markers and clinical parameters in asthmatic children. J Investig Allergol Clin Immunol 2007, 17:286–291.PubMedGoogle Scholar
  25. 25.
    Cantani A, Micera M: Significant decrease of IgE antibodies after a three-year controlled study of specific immunotherapy to pollen allergens in children with allergic asthma. Eur Rev Med Pharmacol Sci 2005, 9:103–111.PubMedGoogle Scholar
  26. 26.
    Scadding GK, Brostoff J: Low dose sublingual therapy in patients with allergic rhinitis due to house dust mite. Clin Allergy 1986, 16:483–491.PubMedCrossRefGoogle Scholar
  27. 27.
    Tari MG, Mancino M, Monti G: Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990, 18:277–284.Google Scholar
  28. 28.
    Hirsch T, Sähn M, Leupold W: Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract ( in children. Pediatr Allergy Immunol 1997, 8:21–27.PubMedCrossRefGoogle Scholar
  29. 29.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557–560.PubMedCrossRefGoogle Scholar
  30. 30.
    Röder E, Berger MY, de Groot H, van Wijk RG: Immunotherapy in children and adolescents with allergic rhinoconjunctivitis: a systematic review. Pediatr Allergy Immunol 2008, 19:197–207.PubMedCrossRefGoogle Scholar
  31. 31.
    Hoeks SB, de Groot H, Hoekstra MO: [Sublingual immunotherapy in children with asthma or rhinoconjunctivitis: not enough evidence because of poor quality of the studies; a systematic review of literature]. Ned Tijdschr Geneeskd 2008, 152:261–268.PubMedGoogle Scholar
  32. 32.
    Verhagen AP, de Vet HC, de Bie RA, et al.: The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 1998, 51:1235–1241.PubMedCrossRefGoogle Scholar
  33. 33.
    Bufe A, Eberle P, Franke-Beckmann E, et al.: Phase III trial with grass allergen tablet for sublingual immunotherapy in children. J Allergy Clin Immunol 2008, 121:S127.CrossRefGoogle Scholar
  34. 34.
    Wahn UM, Melac A, Le Gall M: Efficacy and safety of 5 grass pollen sublingual tablets in children and adolescents with grass pollen rhinoconjunctivitis [abstract]. Allergy 2008, 63(Suppl 88):s45.Google Scholar
  35. 35.
    Niu CK, Chen WY, Huang JL, et al.: Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006, 100:1374–1383.PubMedCrossRefGoogle Scholar
  36. 36.
    Bahçeciler NN, Isik U, Barlan IB, Basaran MM: Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001, 32:49–55.PubMedCrossRefGoogle Scholar
  37. 37.
    Pham-Thi N, de Blic J, Scheinmann P: Sublingual immunotherapy in the treatment of children. Allergy 2006, 61(Suppl 81):7–10.PubMedCrossRefGoogle Scholar
  38. 38.
    Velarde T: Clinical efficacy and safety of sublingual immunotherapy with standardized extracts in the treatment of allergic asthma caused by Dermatophagoides pteronyssinus in Mexican children [in Spanish]. Rev Sanid Milit Mex 2002, 56:10–14.Google Scholar
  39. 39.
    Cox L: Sublingual immunotherapy in pediatric allergic rhinitis and asthma: efficacy, safety, and practical considerations. Curr Allergy Asthma Rep 2007, 7:410–420.PubMedCrossRefGoogle Scholar
  40. 40.
    Savolainen J, Jacobsen L, Valovirta E: Sublingual immunotherapy in children modulates allergen-induced in vitro expression of cytokine mRNA in PBMC. Allergy 2006, 61:1184–1190.PubMedCrossRefGoogle Scholar
  41. 41.
    Savolainen J, Nieminen K, Laaksonen K, et al.: Allergeninduced in vitro expression of IL-18, SLAM and GATA-3 mRNA in PBMC during sublingual immunotherapy. Allergy 2007, 62:949–953.PubMedCrossRefGoogle Scholar
  42. 42.
    Rolinck-Werninghaus C, Kopp M, Liebke C, et al.: Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int Arch Allergy Immunol 2005, 136:134–141.PubMedCrossRefGoogle Scholar
  43. 43.
    Dehlink E, Eiwegger T, Gerstmayr M, et al.: Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006, 36:32–39.PubMedCrossRefGoogle Scholar
  44. 44.
    Antúnez C, Mayorga C, Corzo JL, et al.: Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. Pediatr Allergy Immunol 2008, 19:210–218.PubMedCrossRefGoogle Scholar
  45. 45.
    Akcakaya N, Hassanzadeh A, Camcioglu Y, Cokugras H: Local and systemic reactions during immunotherapy with adsorbed extracts of house dust mite in children. Ann Allergy Asthma Immunol 2000, 85:317–321.PubMedGoogle Scholar
  46. 46.
    Keskin O, Tuncer A, Yildirim S, et al.: Does specific immunotherapy injection cause an increase in bronchial reactivity? J Asthma 2005, 42:765–768.PubMedCrossRefGoogle Scholar
  47. 47.
    Kleine-Tebbe J, Ribel M, Herold DA: Safety of a SQ-standardised grass allergen tablet for sublingual immunotherapy: a randomized, placebo-controlled trial. Allergy 2006, 61:181–184.PubMedCrossRefGoogle Scholar
  48. 48.
    Ibanez MD, Kaiser F, Knecht R, et al.: Safety of specific sublingual immunotherapy with SQ standardized grass allergen tablets in children. Pediatr Allergy Immunol 2007, 18:516–522.PubMedCrossRefGoogle Scholar
  49. 49.
    Eifan AO, Keles S, Bahceciler NN, Barlan IB: Anaphylaxis to multiple pollen allergen sublingual immunotherapy. Allergy 2007, 62:567–568.PubMedCrossRefGoogle Scholar
  50. 50.
    Blazowski L: Anaphylactic shock because of sublingual immunotherapy overdose during third year of maintenance dose. Allergy 2008, 63:374.PubMedCrossRefGoogle Scholar
  51. 51.
    Durham SR, Yang WH, Pedersen MR, et al.: Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006, 117:802–809.PubMedCrossRefGoogle Scholar
  52. 52.
    Didier A, Malling HJ, Worm M, et al.: Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007, 120:1338–1345.PubMedCrossRefGoogle Scholar
  53. 53.
    Brimnes J, Rask C, Urioste S, Lund K: Shorter dosing intervals of sublingual immunotherapy lead to more efficacious treatment in a mouse model of rhinitis. J Allergy Clin Immunol 2008, 121:s263.CrossRefGoogle Scholar
  54. 54.
    Calderon MA, Birk AO, Andersen JS, Durham SR: Prolonged preseasonal treatment phase with Grazax sublingual immunotherapy increases clinical efficacy. Allergy 2007, 62:958–961.PubMedCrossRefGoogle Scholar
  55. 55.
    Radulovic S, Wilson S, Durham S: Sublingual immunotherapy for allergic rhinitis: an updated Cochrane systematic review and meta-analysis [abstract]. Allergy 2007, 62:263.Google Scholar
  56. 56.
    Vourdas D, Syrigou E, Potamianou P, et al.: Double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized olive pollen extract in pediatric patients with allergic rhinoconjunctivitis and mild asthma due to olive pollen sensitization. Allergy 1998, 53:662–672.PubMedCrossRefGoogle Scholar
  57. 57.
    Lue KH, Lin YH, Sun HL, et al.: Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006, 17:408–415.PubMedCrossRefGoogle Scholar
  58. 58.
    Rienzo VD, Minelli M, Musarra A, et al.: Post-marketing survey on the safety of sublingual immunotherapy in children below the age of 5 years. Clin Exp Allergy 2005, 35:560–564.PubMedCrossRefGoogle Scholar
  59. 59.
    Fiocchi A, Pajno G, La Grutta S, et al.: Safety of sublingualswallow immunotherapy in children aged 3 to 7 years. Ann Allergy Asthma Immunol 2005, 95:254–258.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Hospital Médica SurMexico D.F.Mexico

Personalised recommendations